Scholarlink

Background <p>Liver fibrosis is a serious comorbidity of type 2 diabetes mellitus (T2DM) in which non-invasive indices such as FIB-4 are used to monitor hepatic health. This study assesses the impact of GLP-1 receptor agonists (GLP-1RA), SGLT2 inhibitors (SGLT2i), and their combinations on FIB-4 scores in people with T2DM.</p> Methods <p>We conducted a retrospective analysis of 133 adults with T2DM on one of the three treatment regimens, with FIB-4 calculated at baseline and after 12&#xa0;months.</p> Results <p>FIB-4 scores had significantly declined in all groups at 12-month follow-up. The GLP-1RA group exhibited the largest average reduction in FIB-4 (0.280, <i>p</i> &lt; 0.001), followed by combination therapy (0.231, <i>p</i> = 0.001) and SGLT2i (0.206, <i>p</i> &lt; 0.001). All treatment groups experienced significant improvements in glycemia and body weight.</p> Conclusions <p>GLP-1RA and SGLT2i, either alone or in combination, may reduce liver fibrosis risk in T2DM patients as reflected by improved FIB-4 scores.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus

  • 期刊论文

  • 发表日期：

    2025年12月19日

查看全文
  • Virginia Markoutsaki,
  • Georgios Dimakopoulos,
  • Emmanouil Sinakos,
  • Kalliopi Kotsa,
  • Theocharis Koufakis

摘要

Background

Liver fibrosis is a serious comorbidity of type 2 diabetes mellitus (T2DM) in which non-invasive indices such as FIB-4 are used to monitor hepatic health. This study assesses the impact of GLP-1 receptor agonists (GLP-1RA), SGLT2 inhibitors (SGLT2i), and their combinations on FIB-4 scores in people with T2DM.

Methods

We conducted a retrospective analysis of 133 adults with T2DM on one of the three treatment regimens, with FIB-4 calculated at baseline and after 12 months.

Results

FIB-4 scores had significantly declined in all groups at 12-month follow-up. The GLP-1RA group exhibited the largest average reduction in FIB-4 (0.280, p < 0.001), followed by combination therapy (0.231, p = 0.001) and SGLT2i (0.206, p < 0.001). All treatment groups experienced significant improvements in glycemia and body weight.

Conclusions

GLP-1RA and SGLT2i, either alone or in combination, may reduce liver fibrosis risk in T2DM patients as reflected by improved FIB-4 scores.